Eosinophilic esophagitis treatment trial
Summary
A clinical research study to evaluating the safety and tolerability of 2 mg once daily vs. 1 mg twice daily budesonide orodispersible tablets in study participants with eosinophilic
esophagitis
Eligibility
Eligible gender: Male, Female
Eligible ages: 18 to 75
Inclusion criteria:
You may be eligible to participate in this trial if you are:
- between the age of 18 to 75 years
- have been diagnosed with eosinophilic esophagitis
Doctors will also evaluate other criteria to make sure you qualify for the study.
Exclusion criteria:
You may not be eligible to participate in this trial if you:
- have gastroesophageal reflux disease (GERD), Achalasia, sclerosis
- female who is breast feeding or pregnant
Doctors will also evaluate other criteria to make sure you qualify for the study.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
You may contact Dr. Milli Gupta at 403-956-2469 or Milli.Gupta@albertahealthservices.ca with any questions or concerns about the research or your participation in this study.
Principal investigator:
Christopher Ma
Clinical trial:
Yes
REB-ID:
REB22-0539